Your browser doesn't support javascript.
loading
Clinical research progress of dual orexin receptor antagonist lemborexant in the treatment of insomnia / 中华神经科杂志
Chinese Journal of Neurology ; (12): 659-664, 2022.
Article en Zh | WPRIM | ID: wpr-933837
Biblioteca responsable: WPRO
ABSTRACT
In past two decades, understanding of the role of the orexin system in regulating sleep and wakefulness has increased rapidly. Lemborexant, as a dual orexin receptor antagonist, has been approved in some countries for the treatment of insomnia disorders. Existing studies have shown that its safety and tolerability are significantly superior to traditional hypnotic drugs, and it will be new option for treating insomnia disorders. This article reviews the pharmacology, clinical efficacy and safety of lemborexant.
Palabras clave
Texto completo: 1 Base de datos: WPRIM Idioma: Zh Revista: Chinese Journal of Neurology Año: 2022 Tipo del documento: Article
Texto completo: 1 Base de datos: WPRIM Idioma: Zh Revista: Chinese Journal of Neurology Año: 2022 Tipo del documento: Article